The Motley Fool

GlaxoSmithKline plc Makes £629m Indian Investment

The shares of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) slipped 4p lower to 1,566p during early trade this morning after the pharmaceutical group announced it would purchase a further 24% of its Indian subsidiary.

The FTSE 100 member confirmed it would invest £629m to increase its holding in Glaxo Pharmaceuticals Limited from 51% to 75%. GSK revealed it would pay 3,100 rupees for each Glaxo Pharmaceuticals share, equivalent to a 26% premium to the share price on Friday, for the additional stake.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

The £629m transaction is also equivalent to a 13p per share GSK dividend.

GSK’s Indian subsidiary reported sales of £313m and pre-tax profits of £116m during 2012, while its share price has risen 19% during the last twelve months.

David Redfern, GSK’s chief strategy officer:

For GSK this transaction will increase exposure to a strategically important market and for our Indian pharmaceuticals subsidiary’s shareholders we believe it offers a good liquidity opportunity at an attractive premium.

GSK has a proud heritage in India. Today’s announcement is a further demonstration of our long-term commitment to the country having increased our holding in our consumer business earlier this year and more recently committed to a significant manufacturing investment.

Mr Redfern also claimed the deal would be “earnings neutral” next year and “accretive thereafter“.

Prior to today, City experts were forecasting GSK’s 2013 results to show earnings of 115p per share and a dividend of 77p per share.

Following this morning’s price movement, GSK’s P/E could be 13.6 while the dividend may be 4.9%.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

> Maynard does not own any share mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.